MedTrace Logo

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

NCT01808950 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2016-06-22

Study results available
· View outcomes & findings →

Summary

The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.

Conditions

  • Nodular Basal Cell Carcinoma

Interventions

DRUG

0.06% Resiquimod Gel - A

single 60mg dose

DRUG

0.06% Resiquimod Gel - B

single 100mg dose

DRUG

0.06% Resiquimod Gel - C

shave biopsy of BCC followed by single 100mg dose

Sponsors & Collaborators

  • Spirig Pharma Ltd.

    lead INDUSTRY

Principal Investigators

  • R Dummer, PrMD · Clinical Dermatolgy Zurich

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01808950 on ClinicalTrials.gov